Patent ID: 8758825

Claim:
An oral dosage form consisting of an opioid agonist, an opioid antagonist, one or more hydrophobic materials, and additional pharmaceutically acceptable excipients, wherein the opioid antagonist is naltrexone or a pharmaceutically acceptable salt thereof and all of the opioid antagonist in the dosage form is sequestered with the one or more hydrophobic materials such that the opioid antagonist is substantially not released when the dosage form is administered intact but is released in an effective amount to eliminate the euphoric effect of the opioid agonist when the dosage form is tampered with by means of crushing, shearing, grinding, chewing, dissolution in a solvent, heating or any combination thereof, and wherein the dosage form which is administered intact provides a mean Cmax of naltrexone of 30 pg/ml or less, based on oral administration of the dosage form containing 1 mg of naltrexone or the pharmaceutically acceptable salt thereof.